AstraZeneca made $10 billion bid for obesity drugmaker Rhythm, WSJ reports reut.rs/4zshz0f
AstraZeneca made $10 billion bid for obesity drugmaker Rhythm, WSJ reports
AstraZeneca made an about $10 billion offer to acquire obesity drugmaker Rhythm Pharmaceuticals , the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
reut.rs
November 4, 2026 at 9:15 PM
AstraZeneca made $10 billion bid for obesity drugmaker Rhythm, WSJ reports reut.rs/4zshz0f
Indian drugmaker Dr Reddy's gets Brazil regulator nod to sell generic Ozempic reut.rs/4sHh281
Indian drugmaker Dr Reddy's gets Brazil regulator nod to sell generic Ozempic
Indian drugmaker Dr Reddy's Laboratories said on Thursday it had received regulatory approval in Brazil to market and sell a generic version of Novo Nordisk's blockbuster diabetes drug Ozempic.
reut.rs
November 5, 2026 at 5:50 AM
Indian drugmaker Dr Reddy's gets Brazil regulator nod to sell generic Ozempic reut.rs/4sHh281
Indian drugmaker Dr Reddy's Laboratories said on Thursday it had received regulatory approval in Brazil to market and sell a generic version of Novo Nordisk's blockbuster diabetes drug Ozempic.
Indian drugmaker Dr Reddy's gets Brazil regulator nod to sell generic Ozempic
Indian drugmaker Dr Reddy's Laboratories said on Thursday it had received regulatory approval in Brazil to market and sell a generic version of Novo Nordisk's blockbuster diabetes drug Ozempic.
reut.rs
November 5, 2026 at 5:50 AM
Indian drugmaker Dr Reddy's Laboratories said on Thursday it had received regulatory approval in Brazil to market and sell a generic version of Novo Nordisk's blockbuster diabetes drug Ozempic.
The Danish drugmaker raised its guidance for the year after noting an improved outlook for its key obesity and diabetes drugs, particularly in markets outside of the U.S. on.wsj.com/4zlCfXC
Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues
The Danish drugmaker raised its guidance for the year after noting an improved outlook for its key obesity and diabetes drugs, particularly in markets outside of the U.S.
on.wsj.com
November 4, 2026 at 7:21 AM
The Danish drugmaker raised its guidance for the year after noting an improved outlook for its key obesity and diabetes drugs, particularly in markets outside of the U.S. on.wsj.com/4zlCfXC
#econsky
How an #Indian #Drugmaker Broke Into America's #PharmaMarket
Asia on Wall Street on Dr. Power Law explores lesser-known U.S.-listed Asian firms, business models & growth.
This episode follows Dr. Reddy’s American expansion.
youtu.be/5GjYDWoplIA
How an #Indian #Drugmaker Broke Into America's #PharmaMarket
Asia on Wall Street on Dr. Power Law explores lesser-known U.S.-listed Asian firms, business models & growth.
This episode follows Dr. Reddy’s American expansion.
youtu.be/5GjYDWoplIA
How an Indian Drugmaker Broke Into America's Pharma Market
YouTube video by Dr. Power Law
youtu.be
November 3, 2026 at 8:11 PM
#econsky
How an #Indian #Drugmaker Broke Into America's #PharmaMarket
Asia on Wall Street on Dr. Power Law explores lesser-known U.S.-listed Asian firms, business models & growth.
This episode follows Dr. Reddy’s American expansion.
youtu.be/5GjYDWoplIA
How an #Indian #Drugmaker Broke Into America's #PharmaMarket
Asia on Wall Street on Dr. Power Law explores lesser-known U.S.-listed Asian firms, business models & growth.
This episode follows Dr. Reddy’s American expansion.
youtu.be/5GjYDWoplIA
Read more below about how pharmaceutical executives, including those actively investing in AI, believe predictions from frontier labs about AI curing most diseases in 5-10 years dramatically underestimate the complexity of human biology.
Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren’t Buying It.
No drug designed by artificial intelligence has won FDA clearance, and pharma leaders say biology is the obstacle.
www.wsj.com
November 4, 2026 at 9:48 PM
Read more below about how pharmaceutical executives, including those actively investing in AI, believe predictions from frontier labs about AI curing most diseases in 5-10 years dramatically underestimate the complexity of human biology.
‘“That’s complete BS,” said Jeff Leiden, executive chairman of Vertex Pharmaceuticals. Vertex has used roughly 50 AI companies to comb through its data set of 10,000 drug compounds, Leiden said. Not one managed to generate a working drug.‘ www.wsj.com/tech/ai/sili...
Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren’t Buying It.
No drug designed by artificial intelligence has won FDA clearance, and pharma leaders say biology is the obstacle.
www.wsj.com
November 4, 2026 at 5:00 PM
‘“That’s complete BS,” said Jeff Leiden, executive chairman of Vertex Pharmaceuticals. Vertex has used roughly 50 AI companies to comb through its data set of 10,000 drug compounds, Leiden said. Not one managed to generate a working drug.‘ www.wsj.com/tech/ai/sili...
Silicon Valley Promises #AI Will Cure #Disease. #Drugmaker CEOs Aren’t Buying It. @wsj.com
www.wsj.com/tech/ai/sili...
#MedEd #AIinHealthcare #HealthAI #HealthTech
www.wsj.com/tech/ai/sili...
#MedEd #AIinHealthcare #HealthAI #HealthTech
Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren’t Buying It.
No drug designed by artificial intelligence has won FDA clearance, and pharma leaders say biology is the obstacle.
www.wsj.com
November 4, 2026 at 3:36 PM
Silicon Valley Promises #AI Will Cure #Disease. #Drugmaker CEOs Aren’t Buying It. @wsj.com
www.wsj.com/tech/ai/sili...
#MedEd #AIinHealthcare #HealthAI #HealthTech
www.wsj.com/tech/ai/sili...
#MedEd #AIinHealthcare #HealthAI #HealthTech
Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren’t Buying It. - WSJ
www.wsj.com/tech/ai/sili...
www.wsj.com/tech/ai/sili...
Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren’t Buying It.
No drug designed by artificial intelligence has won FDA clearance, and pharma leaders say biology is the obstacle.
www.wsj.com
November 4, 2026 at 9:00 AM
Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren’t Buying It. - WSJ
www.wsj.com/tech/ai/sili...
www.wsj.com/tech/ai/sili...
Teva profit beats forecasts, raises 2026 revenue estimates reut.rs/4kuNAQy
Teva profit beats forecasts, raises 2026 revenue estimates
Israeli drugmaker Teva Pharmaceutical Industries , reported a higher-than-expected third-quarter profit on Tuesday, as strong sales of a trio of its branded medicines offset declines in generic drugs.
reut.rs
November 3, 2026 at 5:45 PM
Teva profit beats forecasts, raises 2026 revenue estimates reut.rs/4kuNAQy
India orders top drugmaker to halt eye medicine production at plant over quality lapses - https://www.channelnewsasia.com/asia/india-orders-top-drugmaker-halt-eye-medicine-production-plant-over-quality-lapses-6507226
India orders top drugmaker to halt eye medicine production at plant over quality lapses
Indian regulators have escalated action against India's largest drugmaker, Sun Pharma, barring ophthalmic drug production at its Assam factory until it submits a satisfactory compliance report.
www.channelnewsasia.com
October 30, 2026 at 1:01 PM
India orders top drugmaker to halt eye medicine production at plant over quality lapses - https://www.channelnewsasia.com/asia/india-orders-top-drugmaker-halt-eye-medicine-production-plant-over-quality-lapses-6507226
#$AZN has offered about $10 billion to acquire #$RYTM. The non-binding bid values the rare obesity drugmaker at up to $134 a share. notreload.xyz/xy/astrazene...
AstraZeneca $10B Offer for Obesity Drugmaker Rhythm
The non-binding bid values the rare obesity drugmaker at up to $134 a share.
notreload.xyz
November 4, 2026 at 10:32 PM
#$AZN has offered about $10 billion to acquire #$RYTM. The non-binding bid values the rare obesity drugmaker at up to $134 a share. notreload.xyz/xy/astrazene...
AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say
AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say
By Sabrina Valle, Milana Vinn and Amy-Jo Crowley Nov 4 (Reuters) - AstraZeneca made an offer of about $10 billion to acquire obesity drugmaker Rhythm Pharmaceuticals, according to three people
www.centraloregondaily.com
November 4, 2026 at 10:53 PM
AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say
Israeli drugmaker Teva Pharmaceutical Industries , reported on Tuesday a higher-than-expected rise in third-quarter profit, helped by strong sales of a trio of its own drugs to offset declines in copycat medicines.
Teva Pharmaceutical Q3 profit gain beats estimates
Israeli drugmaker Teva Pharmaceutical Industries , reported on Tuesday a higher-than-expected rise in third-quarter profit, helped by strong sales of a trio of its own drugs to offset declines in copycat medicines.
reut.rs
November 3, 2026 at 4:05 PM
Israeli drugmaker Teva Pharmaceutical Industries , reported on Tuesday a higher-than-expected rise in third-quarter profit, helped by strong sales of a trio of its own drugs to offset declines in copycat medicines.
India orders top drugmaker to halt eye medicine production at plant over quality lapses
Indian regulators have escalated action against India's largest drugmaker, Sun Pharma…
https://www.vublox.com/posts/india-orders-top-drugmaker-to-halt-eye-medicine-production-at-plant-over-quality-lapses-2o7wzk
Indian regulators have escalated action against India's largest drugmaker, Sun Pharma…
https://www.vublox.com/posts/india-orders-top-drugmaker-to-halt-eye-medicine-production-at-plant-over-quality-lapses-2o7wzk
India orders top drugmaker to halt eye medicine production at plant over quality
Indian regulators have escalated action against India's largest drugmaker, Sun Pharma, barring ophthalmic drug production at its Assam factory until it submits a satisfactory compliance report.
www.vublox.com
October 30, 2026 at 1:02 PM
India orders top drugmaker to halt eye medicine production at plant over quality lapses
Indian regulators have escalated action against India's largest drugmaker, Sun Pharma…
https://www.vublox.com/posts/india-orders-top-drugmaker-to-halt-eye-medicine-production-at-plant-over-quality-lapses-2o7wzk
Indian regulators have escalated action against India's largest drugmaker, Sun Pharma…
https://www.vublox.com/posts/india-orders-top-drugmaker-to-halt-eye-medicine-production-at-plant-over-quality-lapses-2o7wzk
· #AcademicSky · #MedSky · #AI ·
“The promises are grandiose: Anthropic’s chief executive said artificial intelligence could cure most human diseases within a decade. Another tech exec joked that AI researchers have started smoking cigarettes because they are so confident AI will cure lung cancer.”
“The promises are grandiose: Anthropic’s chief executive said artificial intelligence could cure most human diseases within a decade. Another tech exec joked that AI researchers have started smoking cigarettes because they are so confident AI will cure lung cancer.”
Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren’t Buying It.
No drug designed by artificial intelligence has won FDA clearance, and pharma leaders say biology is the obstacle.
www.wsj.com
November 4, 2026 at 11:49 PM
· #AcademicSky · #MedSky · #AI ·
“The promises are grandiose: Anthropic’s chief executive said artificial intelligence could cure most human diseases within a decade. Another tech exec joked that AI researchers have started smoking cigarettes because they are so confident AI will cure lung cancer.”
“The promises are grandiose: Anthropic’s chief executive said artificial intelligence could cure most human diseases within a decade. Another tech exec joked that AI researchers have started smoking cigarettes because they are so confident AI will cure lung cancer.”
Novo loses share in Brazil to cheaper generics, but holds up in Canada and India reut.rs/4ehc8bV
Novo loses share in Brazil to cheaper generics, but holds up in Canada and India
Novo Nordisk is losing market share in Brazil after its semaglutide patent expired, driving a 3% decline in emerging market sales in the third quarter, CEO Mike Doustdar told Reuters, while the drugmaker has largely held its ground in Canada and India.
reut.rs
November 4, 2026 at 12:10 PM
Novo loses share in Brazil to cheaper generics, but holds up in Canada and India reut.rs/4ehc8bV
Bayer says it's "working on" an MFN deal, as most of its large pharma peers have already struck pricing agreements.
Bayer CEO says company is ‘working on’ MFN in the US
Bayer CEO Bill Anderson says the drugmaker is working on an MFN pricing deal with the Trump administration, its first public confirmation of talks.
endpoints.news
November 3, 2026 at 3:04 PM
Bayer says it's "working on" an MFN deal, as most of its large pharma peers have already struck pricing agreements.
India orders top drugmaker to halt eye medicine production at plant over quality lapses
Indian regulators have escalated action against India's
https://www.vublox.com/posts/india-orders-top-drugmaker-to-halt-eye-medicine-production-at-plant-over-quality-lapses-2o7wzk?utm_source=bluesky
Indian regulators have escalated action against India's
https://www.vublox.com/posts/india-orders-top-drugmaker-to-halt-eye-medicine-production-at-plant-over-quality-lapses-2o7wzk?utm_source=bluesky
https://www.vublox.com/posts/india-orders-top-drugmaker-to-halt-eye-medicine-production-at-plant-over-quality-lapses-2o7wzk?utm_source=bluesky
www.vublox.com
October 30, 2026 at 1:02 PM
India orders top drugmaker to halt eye medicine production at plant over quality lapses
Indian regulators have escalated action against India's
https://www.vublox.com/posts/india-orders-top-drugmaker-to-halt-eye-medicine-production-at-plant-over-quality-lapses-2o7wzk?utm_source=bluesky
Indian regulators have escalated action against India's
https://www.vublox.com/posts/india-orders-top-drugmaker-to-halt-eye-medicine-production-at-plant-over-quality-lapses-2o7wzk?utm_source=bluesky
Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren’t Buying It.
https://www.wsj.com/tech/ai/silicon-...
https://www.wsj.com/tech/ai/silicon-...
November 4, 2026 at 12:20 PM
Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren’t Buying It.
https://www.wsj.com/tech/ai/silicon-...
https://www.wsj.com/tech/ai/silicon-...
Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren’t Buying It. - WSJ
www.wsj.com/tech/ai/sili...
www.wsj.com/tech/ai/sili...
Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren’t Buying It.
No drug designed by artificial intelligence has won FDA clearance, and pharma leaders say biology is the obstacle.
www.wsj.com
November 4, 2026 at 9:58 AM
Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren’t Buying It. - WSJ
www.wsj.com/tech/ai/sili...
www.wsj.com/tech/ai/sili...
AstraZeneca is reportedly bidding about $10B to acquire obesity drugmaker Rhythm Pharmaceuticals at roughly $124 per share, according to the WSJ. Neither company has confirmed the offer.
Dropping $10B on niche metabolic treatments shows the steep entry price for big pharma chasing the obesity boom.
Dropping $10B on niche metabolic treatments shows the steep entry price for big pharma chasing the obesity boom.
AstraZeneca Offered $10 Billion to Acquire Obesity Drugmaker Rhythm, WSJ Reports
AstraZeneca made an unconfirmed offer of about $10B to acquire obesity drugmaker Rhythm Pharmaceuticals, according to WSJ reporting.
zubiqo.com
November 4, 2026 at 10:30 PM
AstraZeneca is reportedly bidding about $10B to acquire obesity drugmaker Rhythm Pharmaceuticals at roughly $124 per share, according to the WSJ. Neither company has confirmed the offer.
Dropping $10B on niche metabolic treatments shows the steep entry price for big pharma chasing the obesity boom.
Dropping $10B on niche metabolic treatments shows the steep entry price for big pharma chasing the obesity boom.
